SARS News and Research

RSS

Experts advise not to make COVID-19 crisis worse by rushing for cures

People have died from overdoses of unproven cures in past pandemics. In an editorial published today in Australian Prescriber, Associate Professor Darren Roberts from St Vincent’s Hospital in Sydney and Dr Alexandra Bennett from the NSW Therapeutic Advisory Group advise we should not make the current COVID-19 crisis worse by using medicines based on inadequate evidence.

11 May 2020

New guidelines will help countries across the world to manage hypertension

A new global set of guidelines released today (International Society of Hypertension 2020 Global Hypertension Practice Guidelines) will help countries across the world manage hypertension, which is particularly critical in the current COVID-19 environment.

11 May 2020

Italy develops vaccine candidate that neutralizes SARS-CoV-2 in mice

As the world grapples with the coronavirus disease (COVID-19), scientists race to develop treatments and vaccines to combat the viral infection. Though many ongoing trials show promise in fighting the novel coronavirus, Italian researchers claim they have developed a vaccine that can neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal cells.

10 May 2020

No evidence COVID-19 is spread by fecal-oral transmission

A new study published on the preprint server medRxiv* in May 2020 shows that in patients who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pharyngeal and fecal samples, the virus persists longer in the fecal samples than in the pharyngeal samples. However, fecal-oral transmission does not appear to occur.

10 May 2020

Human neutralizing antibody pair blocks COVID-19-ACE2 binding

With the ongoing COVID-19 pandemic carving its deadly path across the world, and no end in sight in the immediate future, researchers are working furiously to bring out an effective therapeutic drug or vaccine that will stop the virus in its tracks.

10 May 2020

COVID-19 could accelerate activation of dormant tuberculosis (TB)

The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).

10 May 2020

Neutralizing SARS-CoV-2 via S protein

A new study published on the preprint server bioRxiv* in May 2020 reports on a method to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by destroying its main spike protein, which is responsible for attachment to the host cell membrane.

10 May 2020

Low-molecular-weight drugs could help against COVID-19 says study

Chinese researchers have worked on using existing low molecular weight drugs to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

10 May 2020

Reproduction number of COVID-19 and how it relates to public health measures

A new study published on the preprint server medRxiv in May 2020 reports the use of a dynamic SEIR model to identify variations in the reproductive number of SARS-CoV-2 over time, using machine learning techniques. This could help to model and predict the outcomes of various public health solutions.

10 May 2020

Study demonstrates dynamic and broad-scale immune alterations in COVID-19 patient

A new case report released on the preprint server medRxiv* provides a detailed longitudinal analysis of the immune response associated with a fatal case of coronavirus disease (COVID-19). It highlights the need for addressing the source of hyper inflammation in the treatment approach.

10 May 2020

Study shows COVID-19 vulnerability is highly dependent on host genetic architecture

A new US study available on the preprint server medRxiv reveals certain genetic variations that are associated with infection susceptibility and diverse clinical presentation of coronavirus disease (COVID-19) – including asymptomatic cases and severe forms of the disease in younger patients.

10 May 2020

ACE inhibitors should not be discontinued over fears about COVID-19, say researchers

Researchers in Europe have found no evidence to support previous reports that the use of drugs that target the renin-angiotensin-aldosterone system (RAAS) increases susceptibility to coronavirus disease 2019 (COVID-19). The research is published in the European Heart Journal.

10 May 2020

Understanding the ability of COVID-19 virus to infect pets and livestock

A new paper identifies the critical need for research on the ability of the COVID-19 virus to infect certain animal species, the transmissibility of infection between humans and those animals, and the impact infection could have on food security and the economy.

9 May 2020

Perspective: Finding the fastest pathway to COVID-19 vaccine development

When seeking the fastest pathway to a vaccine to prevent coronavirus disease 19 (COVID-19), defining the stakes and potential hurdles is critical, says Barney Graham in this Perspective.

9 May 2020

Scientists create German COVID-19 OMICS Initiative to accelerate research

How does the new coronavirus (SARS-CoV-2) change its genetic information? What other infections occur in patients with COVID-19? Are there genetic risk factors that favor an infection? Numerous genome researchers are pooling their expertise and sequencing infrastructure to make a scientific contribution to manage the COVID-19 pandemic.

9 May 2020

NIH clinical trial evaluates antiviral plus anti-inflammatory drug for COVID-19

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for coronavirus disease 2019 (COVID-19) has begun.

8 May 2020

Study shows how air pollution makes COVID-19 mortality worse for marginalized populations

As scientists worldwide race to gather data about the novel coronavirus, one of the more surprising findings has been detecting the virus attached to fine particles of air pollution.

8 May 2020

FDA grants emergency approval for first at-home saliva-based coronavirus test

Rutgers' RUCDR Infinite Biologics received an amended emergency use authorization from the FDA late Thursday for the first SARS-CoV-2 coronavirus test that will allow people to collect their own saliva at home and send to a lab for results.

8 May 2020

Intervention strategy based on shield immunity could reduce risk of expanding economic activity

While attention remains focused on the number of COVID-19 deaths and new cases, a separate statistic - the number of recovered patients - may be equally important to the goal of minimizing the pandemic's infection rate as shelter-in-place orders are lifted.

8 May 2020

Repurposing existing drugs is a more rapid alternative than developing COVID-19 vaccine

Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.

8 May 2020